- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Carlson Highlights Top NCCN Meeting Takeaway
The National Comprehensive Cancer Network (NCCN) Guidelines may be successful historically, but the network isn't resting on its laurels, Robert Carlson, MD, chief executive officer, said at the NCCN 20th Annual Meeting.
The National Comprehensive Cancer Network (NCCN) Guidelines may be successful historically, but the network isn't resting on its laurels, Robert Carlson, MD, chief executive officer, said at the NCCN 20th Annual Conference, which is taking place March 12-14 in Hollywood, Florida.
the guidelines
Some of those changes include the addition of cost data to chemotherapy templates and resource stratification that will make availaible to all settings around the world to use.
"So I think that the real news is that really we're going to see a transformation in what clinical guidelines are," Dr Carlson said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
